Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada

Introduction The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival (PFS) in gastrointestinal neuroendocrine tumors (NETs), however, no head-to-head comparison exists. We compared treatment patterns and efficacy in a small bowel a...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ashley Paul MD, Shehara Mendis MBBS, Michael Diaz-Stewart BSc, Justin Jao BSc, Melina Boutin MD, Maria Safro MD, Marie-Hélène Denault MD, Caroline Speers BA, CHIM, Heather Stuart MD, Sharlene Gill MD, Daniel J. Renouf MD, David F. Schaeffer MD, David Farnell MD, Jonathan M. Loree MD
Formato:	Artigo
Idioma:	Inglês
Publicado:	SAGE Publishing 2026-02-01
Series:	Cancer Control
Acceso en liña:	https://doi.org/10.1177/10732748261417423
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!